Dr. Vladimir Kushnir, MD
Claim this profileWashington University School of Medicine
Studies Pancreatic Cancer
Studies Esophageal Cancer
8 reported clinical trials
15 drugs studied
Affiliated Hospitals
Clinical Trials Vladimir Kushnir, MD is currently running
Endoscopic Therapy vs Surveillance
for Barrett's Esophagus
The purpose of this study is to learn the best approach to treating patients with known or suspected Barrett's esophagus by comparing endoscopic surveillance to endoscopic eradication therapy. To diagnose and manage Barrett's esophagus and low-grade dysplasia, doctors commonly use procedures called endoscopic surveillance and endoscopic eradication therapy. Endoscopic surveillance is a type of procedure where a physician will run a tube with a light and a camera on the end of it down the patients throat and remove a small piece of tissue. The piece of tissue, called a biopsy, is about the size of the tip of a ball-point pen and is checked for abnormal cells and cancer cells. Endoscopic eradication therapy is a kind of surgery which is performed to destroy the precancerous cells at the bottom of the esophagus, so that healthy cells can grow in their place. It involves procedures to either remove precancerous tissue or burn it. These procedures can have side effects, so it is not certain whether risking those side effects is worth the benefit people get from the treatments. While both of these procedures are widely accepted approaches to managing the condition, there is not enough research to show if one is better than the other. Barrett's esophagus and low-grade dysplasia does not always worsen to high-grade dysplasia and/or cancer. In fact, it usually does not. So, if a patient's dysplasia is not worsening, doctors would rather not put patients at risk unnecessarily. On the other hand, endoscopic eradication therapy could possibly prevent the worsening of low-grade dysplasia into high-grade dysplasia or cancer (esophageal adenocarcinoma) in some patients. Researchers believe that the results of this study will help doctors choose the safest and most effective procedure for their patients with Barrett's esophagus and low-grade dysplasia. This is a multicenter study involving several academic, community and private hospitals around the United States. Up to 530 participants will be randomized. This study will also include a prospective observational cohort study of up to 150 Barrett's esophagus and low grade dysplasia patients who decline randomization in the randomized control trial but undergo endoscopic surveillance (Cohort 1) or endoscopic eradication therapy (Cohort 2), and are willing to provide longitudinal observational data.
Recruiting1 award N/A
WATS-3D Tissue Sampling
for Barrett's Esophagus Detection
Esophageal cancer is a deadly disease that is becoming increasingly common in the United States. Barrett's esophagus (BE) is a pre-cancerous state that can develop into esophageal cancer, but is highly treatable. Progression of BE to esophageal cancer is still common due to missed diagnosis of Barrett's esophagus recurrence following treatment. Wide-Area Trans-Epithelial Sampling (WATS-3D) is a new technology that uses brush sampling to examine larger areas of the esophagus as compared to conventional biopsies. Preliminary studies show improved detection of cancerous changes in Barrett's esophagus surveillance. The investigators hope to see if the addition of WATS-3D increases the rate of detection of recurrent BE following treatment, which is of the utmost importance since it would allow for earlier re-treatment of disease and ultimately allow for prevention of progression to esophageal cancer.
Recruiting1 award N/A
More about Vladimir Kushnir, MD
Clinical Trial Related7 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Vladimir Kushnir, MD has experience with
- Optical Coherence Tomography Probe
- Stereotactic Body Radiotherapy
- Defactinib
- Nivolumab
- Nab-paclitaxel
- Peripheral Blood
Breakdown of trials Vladimir Kushnir, MD has run
Pancreatic Cancer
Esophageal Cancer
Colon Cancer
Rectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Vladimir Kushnir, MD specialize in?
Vladimir Kushnir, MD focuses on Pancreatic Cancer and Esophageal Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage III patients, or patients who are undergoing treatment.
Is Vladimir Kushnir, MD currently recruiting for clinical trials?
Yes, Vladimir Kushnir, MD is currently recruiting for 2 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Vladimir Kushnir, MD has studied deeply?
Yes, Vladimir Kushnir, MD has studied treatments such as Optical coherence tomography probe, Stereotactic Body Radiotherapy, Defactinib.
What is the best way to schedule an appointment with Vladimir Kushnir, MD?
Apply for one of the trials that Vladimir Kushnir, MD is conducting.
What is the office address of Vladimir Kushnir, MD?
The office of Vladimir Kushnir, MD is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.